Need some help? Close Help


Health & Fitness
UK - East
Date Rated:
Valuation (Pre Money):
Industry: Health & Fitness
Location: UK - East
Platform: Crowdcube
£1,000,000 Expansion
Valuation: £9,000,900
Date Rated: 08/12/17



Tax Status: EIS

Business Summary

Regenerys supplies human tissue management systems for patients undergoing breast reconstruction following breast cancer treatment and for cosmetic and skin surgery. Regenerys has already developed its Adiposet system and it has been used in over 100 breast reconstruction procedures at 28 hospitals and clinics. This round of investment will be mainly used to fund marketing and hire staff.

Financial Overview




There is insufficient information available to provide a financial overview



The strong product development and the managerial skills across the team provide the company with the right mix of skills to grow the business in the UK and to start an international expansion.
The management team has evidence of building successful businesses with many years of experience in the industry and they have engaged and experienced advisors on board.
The business has raised £3.7m to develop the product over the past six years and there is now a complete management team full time ready for the commercialisation stage.
Although the initial addressable market in the UK is small, the company has achieved already orders from the UE and the plastic surgery industry is worth over £3bn globally.
The product has already been tested in 26 sites and has several positive testimonials from clinicians and patients about the benefits of using this system.
The company has its own proprietary technology for processing and storage the adipose tissue to provide superior quality and it seems it is the only company licensed by the HTA.
There is insufficient information available to fairly rate this aspect of the business


Given the savings that Regenerys' product offers to its customers versus other techniques, the offering could be adopted rapidly. There are strong barriers to entry in the industry and the company has already many clinician and hospital relationships that should help secure further market share. The team is also developing a range of products in related areas that if patents are granted could provide the business with a competitive edge.

Given that the offering has been used over 100 times, sales estimates of 284 in 2019 and 476 in 2020 seem reasonable: in that case, the Founder has stated that only 25 Adiposet cases and one MySkin case per month are needed to achieve break-even. However, given the high valuation, a larger volume of sales seems needed to achieve material returns for investors.

Related Links

Crowdcube Pitch


Right To Reply

Are you the entrepreneur? If you would like to publish a comment on our rating, please contact the ratings team.

Latest Forum Comments

Read All Comments


The views and opinions expressed on this bulletin board are the sole property and responsibility of the author. Neither Crowdrating nor Wheatfromchaff Ltd, nor any of the directors or officers of Wheatfromchaff Ltd accept any responsibility or liability for them. Readers should be aware that comments do not constitute investment advice and may be inaccurate. Please seek to verify and take advice on all comments before relying on them in the context of any investment decisions you may make. if you wish to use the bulletin board please be aware you are accepting full responsibility and liability for what you write. Please look here for more specific rules we impose on people using our bulletin boards. We moderate all bulletin boards and we reserve the right not to publish your comments.


Your capital is at risk when you invest in shares and debt securities. You can lose some or all of your money and may not be able to realise your investment. Therefore you should should never invest more than you can afford to lose. If in doubt about the suitability or tax implications of any investment, please seek independent financial advice. 

Information published on this website and any other reports or ratings published on or by Wheatfromchaff Limited (trading as Wheatfromchaff) have been prepared by us in the United Kingdom for information purposes only. Wheatfromchaff Ltd is Authorised and Regulated by the Financial Conduct Authority FRN: 751017. 

No content on this website or on any reports or ratings published on this website nor any copy of it, nor any other reports or copies of them published on may be reproduced, redistributed or copied in whole or in part for any purpose. Any and all reports have been approved by, and are being distributed in the UK and the European Union (EU) only and are not to be distributed in any other jurisdictions where their distribution may be restricted by law and persons into whose possession this or any other reports come should inform themselves about and observe such restrictions.

This report and any other reports published on do not constitute an offer or a solicitation to buy or sell any securities referred to herein. It should not be so construed, nor should it or any part of it form the basis of, or be relied on in connection with, any contract or commitment whatsoever. The information on this website or in reports or ratings published by Wheatfromchaff, or on which this or any other reports are based, has been obtained from sources that Wheatfromchaff believes to be reliable and accurate, and in accordance with COBS 2.4 of the FSA Handbook we have verified it to the best of our ability. However, it has not been independently verified and no representation or warranty, express or implied, is made as to the accuracy or completeness of any information obtained from third parties. The information or opinions are provided as at the date of this report or any other report publication dates and are subject to change without notice. The information and opinions provided in this and any other reports take no account of the investors/ individual circumstances and should not be taken as specific advice on the merits of any investment decision. Investors should consider any or all of the reports or ratings we publish as only a single factor in making any investment decisions.  

Wheatfromchaff does not accept any liability whatsoever for any direct or consequential loss however so arising, directly or indirectly, from any use of this report nor its contents. Investors may receive back less that they invested as investments may fall as well as rise in value. Investors should obtain independent advice based on their own circumstances before making investment decisions. By accepting this report you agree to be bound by the foregoing limitations.

The Ratings we publish have been approved and issued at Financial Promotions in the United Kingdom by Wheatfromchaff in the United Kingdom who is Authorised and Regulated by the Financial Conduct Authority FRN: 751017. Wheatfromchaff Limited registered office is Kilver Court, Kilver Street, Shepton Mallet, Somerset, BA4 5NF and telephone number +44 (0) 1749 347 577. Telephone calls may be recorded. VAT No: 214 0196 49

© Wheatfromchaff Ltd All Rights Reserved February 2017